VTI, aka Vertebral Technologies, Inc., headquartered in Minneapolis, Minnesota, has relocated their facilities from Minnetonka, Minnesota to Minneapolis. Brian Thron, director of Marketing, said in the February 16, 2017 news release, “the contemporary space compliments the company’s latest rebrand, with its simplistic design and modern color scheme. I’m pleased to call this space VTI’s new home.”
VTI Moves Facilities to Minneapolis

“VTI’s new ISO Class 8 Controlled Environment is fully operational post the certification and validation testing process. In addition, the new facility allows VTI to take advantage of increased efficiency across multiple departments with a new office layout that encourages collaboration to everyday operations. We are looking forward to these operative advantages moving forward as VTI grows in 2017,” said Director of Manufacturing Brian Holmberg.
President and CEO Matt Kyle stated, “We are excited to be in our new space. The VTI team did a tremendous job of executing the move without disruption. The new space helps everyone align with our organizational objectives and growth focused culture. The feedback we have received, both internal and external, has been very positive.”
Brian Holmberg told OTW, “The new VTI facility design is driving increased efficiency in multiple areas, from reducing turnaround time in customer service to compressing the processing flow of the production cycle. These efficiencies will allow VTI to be more nimble with current and future growth. Ultimately, these improvements will help us better serve our surgeon user base as we expand and grow in the spine market.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.